# Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer

> **NCT07638631** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chen Lizhu** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** Ipilimumab injection N01
- **DRUG:** Sintilimab
- **DRUG:** Modified (60% standard dose) XELOX

## Key facts

- **NCT ID:** NCT07638631
- **Lead sponsor:** Chen Lizhu
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-06-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638631, "Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*